Introduction {#s1}
============

Immune checkpoint inhibitors (ICIs) have proven effective in the treatment of numerous cancers ([@B23]). By inhibiting negative regulators of the immune system, ICIs enhance immune activity against cancer cells and, aberrantly, against host non-cancer cells, resulting in inflammatory side effects also called immune-related adverse events (irAEs) ([@B21]).

Cytokine release syndrome (CRS) is a systemic inflammatory disease characterized by a massive release of cytokines ([@B8]). It can present with a variety of symptoms ranging from mild to life threatening, being sometimes fatal ([@B16]). Mild symptoms of CRS include fever, fatigue, nausea, vomiting, headache, rash, arthralgia, myalgia, and malaise. In most severe cases, hypotension requiring high-dose vasopressors and hypoxia requiring mechanical ventilation may occur as life-threating complications. Moreover, laboratory abnormalities that are common in patients with CRS include cytopenias, coagulopathy, elevated liver enzymes and creatinine, and high C reactive protein levels ([@B25]). CRS can be triggered by infections or be associated with drugs such as monoclonal antibodies (e.g., rituximab), conventional chemotherapy, and immunotherapies with chimeric antigen receptor T (CAR T) cells ([@B25]).

Despite the strict parallelism between ICI mechanism of action and CRS pathophysiologic mechanism, to date, only a few case reports have documented the association of ICIs as pharmacological triggers of CRS in cancer patients ([@B6]; [@B22]; [@B24]; [@B27]; [@B4]; [@B11]; [@B15]; [@B19]).

To describe the burden of ICI-related CRS and raise awareness of CRS as irAE, we retrieved from VigiBase, the World Health Organization (WHO) global database of spontaneously reported suspected adverse drug reactions (ADRs), the largest-to-date series of ICI-related CRS safety reports and assessed the geographical and temporal patterns of reporting, patient demographics and clinical features, treatment characteristics, CRS clinical presentation, timing, seriousness, and outcome.

Methods {#s2}
=======

VigiBase (<http://www.vigiaccess.org/>), developed and maintained by the WHO Collaborating Centre for International Drug Monitoring, Uppsala Monitoring Centre (WHO-UMC), gathers over 20 million anonymized safety reports of suspected ADRs spontaneously reported by physicians, pharmacists, health professional, pharmaceutical companies and patients, from over 130 member countries of the WHO Program for International Drug Monitoring. VigiBase facilitates the detection of drug safety signals, highlights rare ADRs and, through a continuous monitoring, can capture delayed ADRs. Safety reports include administrative information (country of origin, reporting date, seriousness), patient demographics (age at ADR onset and sex), indication, start and end dates of reported drugs, ADRs with onset dates and outcomes. The Medical Dictionary for Regulatory Activities (MedDRA) allows for ADRs' classification according to hierarchical groups, whereby "preferred terms" (PTs) describe ADRs as single medical concepts.

We performed a retrospective observational study and retrieved from VigiBase safety reports associated with ipilimumab (of the anatomical therapeutic chemical, ATC, class L01XC11), nivolumab (L01XC17), pembrolizumab (L01XC18), atezolizumab (L01XC32), avelumab (L01XC31), durvalumab (L01XC28), and cemiplimab (L01XC33), whereby the role of the administered ICI was indicated by reporter as "suspected" for the adverse event(s). Subsequently, among ICI-related safety reports, we selected those reporting as adverse event CRS, defined accordingly to the correspondent MedDRA PT "cytokine release syndrome" (MedDRA version 21.1). The fact that reporters defined the ICI role as "suspected" in CRS onset (and ruled out either an "interacting" or a "concomitant" role), was *per se* the assumption for classifying the safety reports as exposed, even if these did not explicitly record the start and end dates for the ICI treatment as a confirmation. Safety report retrieval ranged from database inception through January 12^th^ 2020.

Based on molecular targets, we distinguished anti-cytotoxic T-lymphocyte antigen-4 agents (anti-CTLA-4, i.e., ipilimumab), from anti-programmed death-1/programmed death-Ligand 1 (anti-PD-1/PD-L1, i.e., pembrolizumab, nivolumab, atezolizumab, avelumab durvalumab, and cemiplimab).

We assessed ICI-related CRS safety reports in terms of geographical and temporal patterns of reporting; patient age and sex; cancer type; treatment characteristics (ICI drug and regimen; co-suspected drugs; duration); CRS clinical presentation, timing, seriousness, and outcome. We summarized categorical variables using frequency and percentage, continuous variables using median, and interquartile range (IQR). Analyses were carried out by Microsoft Excel (2010, Microsoft Corporation, Washington, USA).

According to the Human Research Act (810.30, of September 30^th^, 2011---status as of January 1st, 2014), from the Federal Assembly of the Swiss Confederation, ethical approval was not required (Art. 2: "It does not apply to research which involves anonymously collected or anonymised health-related data").

Results {#s3}
=======

As of January 12^th^ 2020, VigiBase gathered 80,700 safety reports of ICI-related ADRs, among which 58 concerned CRS. The geographical pattern of ICI-related CRS reporting varied across continents. In Australia the proportion of ICI-related CRS cases out of the total number of ICI-related safety reports was the highest (3/2,126, 0.14%), followed by North America (United States and Canada; 37/36,500, 0.10%). Conversely, ICI-related CRS reporting was lower in Europe (12/18,756, 0.06%) and in Japan (6/13,267, 0.05%). [**Table 1**](#T1){ref-type="table"} summarizes baseline characteristics of ICI-related CRS safety reports. ICI-related CRS reporting increased over time, with 27 cases (47%) in 2019 (no cases of ICI-related CRS reported in 2020 as of January 12^th^). Melanoma (n=17, 29%) and hematologic malignancies (n=16, 28%) were the most common underlying cancers. Regardless of cancer type, ICI-related CRS safety reports were more numerous for anti-PD-1/PD-L1 antibodies (43, 74%). ICIs were the solely suspected drugs in 37 (64%) safety reports. Among the other 21 (36%) safety reports with additional suspected drugs, 18 (31%) listed antineoplastic agents. Concurrent infections were reported in six (10%) patients, with pneumonia (n=2), urinary tract infection/cystitis (n=1), upper respiratory tract infection/sinusitis (n=1), *Staphylococcal bacteraemia*/*Pseudomonas* infection (n=1), and sepsis (n=1). CRS was the solely reported ICI-related ADR in 21 (36%) patients. Among the other 37 (64%) safety reports with additional ADRs co-reported with CRS, 25 (43%) listed ADRs that are typical signs and symptoms of CRS ([**Table 2**](#T2){ref-type="table"}). ICI-related CRS developed a median of four weeks after ICI initiation (IQR 1--18 weeks, n=9, 16%). Except for one case of unknown seriousness and two cases (3%) recorded as not serious, reporters evaluated ICI-related CRS cases as serious in 55 (95%) patients. In 25 (43%) cases, ICI-related CRS caused or prolonged hospitalization, in 10 (17%) it was life threatening, and in 18 (31%), CRS determined a clinically relevant condition not further specified. There were two fatal cases, whereby CRS contributed to worsening the condition of the patients along with infections and tumor progression. Beside these latter cases, CRS either recovered or was recovering at the time of reporting in 35 (60%) cases. In 20 (34%) safety reports, CRS outcome was unknown and one patient recovered from ICI-related CRS with sequelae.

###### 

Characteristics of safety reports of immune checkpoint inhibitor-related cytokine release syndrome.

  ----------------------------------------------------------------------------------------------------------
  Characteristics of safety reports                                                          n (%)\
                                                                                             (N=58)
  ------------------------------------------------------------------------------------------ ---------------
  Reporting year                                                                             

   2015                                                                                      5 (9)

   2016                                                                                      3 (5)

   2017                                                                                      6 (10)

   2018                                                                                      17 (29)

   2019                                                                                      27 (47)

  Age                                                                                        

   Reported                                                                                  50 (86)

    Median \[IQR\], years                                                                    55 \[44--68\]

   Not reported                                                                              8 (14)

  Sex                                                                                        

   Male                                                                                      34 (59)

   Female                                                                                    21 (36)

   Not reported                                                                              3 (5)

  Cancer type                                                                                

   Melanoma                                                                                  17 (29)

   Hematologic malignancy[^a^](#fnT1_1){ref-type="table-fn"}                                 16 (28)

   Lung cancer[^b^](#fnT1_2){ref-type="table-fn"}                                            11 (19)

   Other[^c^](#fnT1_3){ref-type="table-fn"}                                                  6 (10)

   Not reported                                                                              8 (14)

  Regimen                                                                                    

   Anti-CTLA-4 (ipilimumab) monotherapy                                                      3 (5)

   Anti-PD-1 monotherapy                                                                     

    Nivolumab                                                                                21 (36)

    Pembrolizumab                                                                            12 (21)

    Cemiplimab                                                                               1 (2)

   Anti-PD-L1 monotherapy                                                                    

    Atezolizumab                                                                             7 (12)

    Avelumab                                                                                 2 (3)

   Nivolumab and ipilimumab combination therapy                                              7 (12)

   Nivolumab and ipilimumab treatment not definable[^d^](#fnT1_4){ref-type="table-fn"}       2 (3)

   Pembrolizumab and ipilimumab treatment not definable[^d^](#fnT1_4){ref-type="table-fn"}   2 (3)

   Pembrolizumab, followed by nivolumab and ipilimumab combination                           1 (2)

  Duration                                                                                   

   Single administration                                                                     10 (17)

   Prolonged                                                                                 10 (17)

    Median \[IQR\], weeks                                                                    11 \[4--24\]

   More than 1 year                                                                          1 (2)

   Not definable[^d^](#fnT1_4){ref-type="table-fn"}                                          37 (64)

  Co-suspected drugs                                                                         

   Not reported                                                                              37 (64)

   Reported                                                                                  21 (36)

    Antineoplastic agents[^e^](#fnT1_5){ref-type="table-fn"}                                 18

    Other[^f^](#fnT1_6){ref-type="table-fn"}                                                 4
  ----------------------------------------------------------------------------------------------------------

IQR, interquartile range; CTLA-4, cytotoxic T-lymphocyte antigen 4; PD-1, programmed cell death protein 1; PD-L1, programmed cell death-ligand 1.

Hodgkin disease (n=5); diffuse large B-cell lymphoma refractory (n=4); diffuse large B-cell lymphoma (n=2); lymphoma, non-Hodgkin's lymphoma refractory, acute myeloid leukemia, primary mediastinal large B-cell lymphoma, acute lymphocytic leukemia (all n=1).

Non-small cell lung cancer (n=5); adenocarcinoma of the lung (n=3); pulmonary carcinoma, squamous cell carcinoma of the lung, lung neoplasm malignant (all n=1).

Alveolar soft part sarcoma (n=2); breast cancer metastatic, gastric cancer, squamous cell carcinoma of skin, triple negative breast cancer (all n=1).

Because of partially recorded or missing ICI start and/or end dates.

Axicabtagene ciloleucel, cyclophosphamide, fludarabine (n=4); brentuximab vedotin, cobimetinib, vemurafenib (n=2); azacitidine, blinatumomab, carboplatin, dabrafenib, decitabine, IMCgp100, NY-ESO-1, pazopanib, pemetrexed, siltuximab, talimogene laherparepvec, tisagenlecleucel, trametinib (all n=1). Some safety reports had multiple co-suspected antineoplastic agents.

Lisinopril and morphine (n=1); mesna, naloxegol, prednisolone (all n=1).

###### 

Co-reported clinical signs and symptoms of immune checkpoint inhibitor-related cytokine release syndrome.

  -------------------------------------------------------------------------------------------------
  Co-reported clinical signs and symptoms of CRS   Number of safety reports\
                                                   n (%)[^a^](#fnT2_1){ref-type="table-fn"}, N=58
  ------------------------------------------------ ------------------------------------------------
  Constitutional                                   13 (22)

   Fatigue                                         2

   Pyrexia                                         8

   Asthenia                                        1

   Malaise                                         1

   Myalgia                                         2

   Arthralgia                                      2

  Skin                                             4 (7)

   Rash                                            2

   Rash maculo-papular                             2

  Gastrointestinal                                 6 (10)

   Diarrhea                                        4

   Nausea                                          3

  Respiratory                                      6 (10)

   Acute respiratory distress syndrome             2

   Respiratory failure                             2

   Pulmonary edema                                 1

   Pleural effusion                                3

   Hypoxia                                         1

  Cardiovascular                                   4 (7)

   Tachycardia                                     2

   Hypotension                                     3

  Renal                                            6 (10)

   Acute kidney injury                             3

   Nephritis                                       1

   Renal failure                                   2

  Neurologic                                       4 (7)

   Headache                                        2

   Hypotonia                                       1

   Tremor                                          1

  Laboratory abnormalities                         3 (5)

   Anemia                                          1

   Platelet count decreased                        2

   Neutrophil count decreased                      1

   Lactic acidosis                                 1

   Thrombocytopenia                                1

   Leukopenia                                      1

   Neutropenia                                     1

   Lymphopenia                                     1

  Coagulation                                      1 (2)

   Disseminated intravascular coagulation          1
  -------------------------------------------------------------------------------------------------

CRS, cytokine release syndrome.

Some patients reported multiple signs and symptoms of cytokine release syndrome.

Discussion {#s4}
==========

By analyzing the WHO global pharmacovigilance database, we described the largest-to-date series of CRS cases reported in association with ICI treatment.

By hyper-activating the immune system to overcome the inhibitory signals of cancer cells, ICIs can provoke on-target autoimmune toxicity (when the targeted tumor antigen is on host non-cancer cells), as well as off-target cytokine-associated toxicity (also known as CRS) ([@B16]). In CRS, T cells, B cells, natural killer cells, macrophages and endothelial cells, release a variety of cytokines, among which interleukin-6 (IL-6) plays a central role ([@B16]). Noteworthy, functional genetic variants in *IL-6* gene have been identified, which lead to IL-6 overexpression ([@B5]). On this basis, the geographical pattern that we observed in the reporting of ICI-related CRS, which was highest in Australia and lowest in Japan, might suggest that polymorphisms in *IL-6* gene could predispose patients to develop CRS upon treatment with ICIs. However, such a variability could also depend on the existence of differences among reporting countries concerning the awareness, recognition, and the extent of spontaneous reporting of CRS as ICI-related ADR.

ICI-related CRS reporting peaked in 2019 suggesting that, albeit likely depending on the progressively increasing use of ICIs for a variety of cancer types, CRS is progressively more easily recognized and diagnosed as associated to ICIs. Accordingly, among the limited isolated case reports published so far on CRS onset during treatment with ICIs, the majority deals with very recent cases, on either pembrolizumab or nivolumab used to treat different cancer types ([@B4]; [@B11]; [@B15]; [@B19]).

CRS represents one of the most frequent serious adverse effects of bispecific antibody constructs and CAR T cell therapies recently approved for hematologic malignancies, such as acute lymphoblastic B cell leukemia, chronic lymphocytic leukemia, and diffuse large B cell lymphoma ([@B12]). Consistently, we observed that the tumor-specific pattern of CRS onset on ICIs involved more commonly patients with hematological malignancies. Moreover, a considerable number of ICI-related CRS cases was reported in patients with melanoma, probably because of the earlier approval of ICIs for this indication ([@B20]; [@B10]).

Regardless of cancer type, ICI-related CRS safety reports were more numerous on anti-PD-1/PD-L1 antibodies, in line with the single case reports of CRS developed on either nivolumab or pembrolizumab ([@B6]; [@B22]; [@B24]; [@B27]; [@B4]; [@B11]; [@B15]; [@B19]). Moreover, a recent review of the largest clinical trials of ICIs ([@B18]), found that the frequency of hematological irAEs of all grades (including CRS), was higher with anti-PD-1 (4.1%) and anti-PD-L1 (4.7%) than with anti-CTLA-4 agents (0.5%, *P* \< 0.0001). However, our finding might also reflect a more widespread use of anti-PD-1/PD-L1 agents in clinical practice as compared to anti-CTLA-4 ([@B13]).

Noteworthy, beyond ICIs, co-suspected drugs were absent in a remarkable proportion of safety reports, suggesting that ICIs could contribute to CRS onset as pharmacological triggers. When otherwise present, co-suspected drugs were mostly antineoplastic agents known from either clinical studies or previous case reports for causing CRS. Among these, the bispecific antibody IMCgp100, the CAR T cell therapy tisagenlecleucel and the antibody-drug conjugate that targets CD30, brentuximab vedotin ([@B2]; [@B7]).

Seven patients reported as co-suspected drugs chemotherapeutic agents. Although the correspondent safety reports lacked information on the timing of chemotherapy administration (which could have been antecedent or concomitant with ICI treatment), the associated lymphocyte-depletion could have affected the risk of CRS development. Indeed, a higher incidence of CRS was observed after lymphocyte-depletion with cyclophosphamide or fludarabine in patients treated with CD19 CAR T cells ([@B9]). Although CRS has been described in the setting of bacterial or viral infections ([@B25]), among the cases that we analyzed, infections were reported in only six patients.

Since CRS is clinically defined by a constellation of inflammatory symptoms and signs, the majority of which is non-specific, its diagnosis can be difficult ([@B8]). Temporal correlation and some abnormal laboratory findings (e.g., increased creatinine, increased liver enzymes, and altered coagulation parameters) represent crucial diagnostic hints of CRS ([@B8]). However, we could not properly evaluate patients' laboratory tests, due to the scant clinical richness of safety reports. Conversely, we described that ICI-related CRS developed with a median of 4 weeks since ICI initiation, which widely fits within the 10-week mean time to onset described for ICI-related hematological ADRs by [@B18] in the resume of 63 case reports among which 7 of ICI-related CRS.

We observed that ICI-related CRS either recovered or was recovering at the time of reporting in most cases, with only two fatal outcomes.

With an exploratory intent and the purpose of generating hypotheses to be potentially tested and confirmed in future studies, on larger datasets and through different data sources and study designs, we assessed the impact of some patient and ICI treatment characteristics on CRS outcome ([**Supplementary Table 1**](#SM1){ref-type="supplementary-material"}). We observed that CRS resolution occurred more frequently in association with female sex. Female sex as a factor that possibly prevents cancer patients from developing severe ICI-related CRS could rely on the existence of differences in the immune response between males and females ([@B14]). However, if efficacy of ICI treatment in advanced cancers was shown not to be affected by patient sex, data on the impact of sex on ICI-related adverse event rate in general are still lacking ([@B1]). Moreover, the reporting frequency of ICI-related recovered/recovering CRS increased in association with younger age, ICI monotherapy rather than the combination, and prolonged treatments (although without reaching statistical significance probably due to small sample size). We highlighted that younger age (defined as \<65 years in the present study) might be more frequently associated with ICI-related CRS positive outcome. This observation, whenever confirmed on a larger number of patients, would suggest that older adults (aged ≥65 years) could be exposed to a higher risk of developing severe CRS, in contrast to the general knowledge of comparable safety profiles of ICIs regardless of patient age ([@B3]). ICI-related CRS having more frequently a positive outcome in association with ICI monotherapy, confirmed the higher toxicity---more severe and with an earlier onset---of ICI combination as compared to single agents ([@B10]). Lastly, the number of ICI-related CRS events with a positive outcome was higher with ICI prolonged treatments, thus supporting former findings about the most serious ICI-related toxicities generally occurring following ICI single administration ([@B26])

Relying on a spontaneous reporting system, VigiBase suffers from some general limitations that include reporting bias (e.g., underreporting and selective reporting) and missing data. With regard to co-reported drugs, it is important to mention that in VigiBase, despite there being no other suspected, interacting, or concomitant drugs specified in the report, other drugs might have been taken by the patient, without being considered sufficiently relevant by reporter to be recorded or were omitted for unknown reasons. Therefore, assessing a causal relationship between a drug and an adverse event is complex and benefits from having the more information available. As safety reports derive from a variety of sources, they contain heterogeneous information and are rarely sufficient to confirm that a particular drug caused the ADR in a specific patient. Moreover, safety reports do not provide information on the number and demographics as well as clinical characteristics of patients exposed to the drug but who did not develop ADRs ([@B17]). Further specific limitations concern the small sample size and the fact that, being CRS a systemic inflammatory condition, a variety of other factors such as infections and other drugs could have triggered it in addition to ICIs ([@B25]). Lastly, because of exclusion from the present case series of safety reports with signs and/or symptoms of CRS reported as separate adverse events on ICIs, without CRS as preferred term, we could have underestimated the number of safety reports associated with ICI(s) concerning suspected CRS.

Conclusions {#s5}
===========

Due to ICI expanding indications, clinicians should be aware that ICIs could contribute to CRS onset in cancer patients as pharmacological triggers. Further studies are needed to better characterize the mechanisms underlying ICI-related CRS.
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